Investigating hsa_circ_0002111's role in cell motility, findings suggest a novel therapeutic target in papillary thyroid carcinoma.
Hsa_circ_0002111 is highly expressed in papillary thyroid carcinoma (PTC). We therefore investigated its role and underlying mechanism in promoting PTC progression. Q-RT-PCR, dual-luciferase reporter assays, AGO2-RIP, CCK-8, colony formation, wound healing, and Transwell assays were employed to dissect the circRNA/miRNA/mRNA axis interactions and their functional phenotypes. Results showed that silencing hsa_circ_0002111 significantly inhibited the viability, migration, and invasion of KTC-1 cells. Mechanistic studies demonstrated that hsa_circ_0002111 acted as a sponge for miR-432-5p, which in turn targeted the 3’UTR of CDKN2B and suppressed its expression. Functional assays revealed that either hsa_circ_0002111 knockdown or miR-432-5p overexpression inhibited migration and invasion, whereas inhibition of miR-432-5p reversed these cellular processes. Consistently, siRNA-mediated knockdown of CDKN2B phenocopied the motility defects observed upon hsa_circ_0002111 silencing, suggesting that CDKN2B is a functionally relevant downstream effector. Thus, the hsa_circ_0002111/miR-432-5p/CDKN2B axis is implicated in papillary thyroid carcinoma progression. These findings revealed a novel regulatory mechanism of hsa_circ_0002111 in KTC-1 cells and suggest its potential as a therapeutic target, offering new insights for future clinical applications and research directions in thyroid cancer.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: